<DOC>
	<DOCNO>NCT01569204</DOCNO>
	<brief_summary>The Purpose trial : - determine complete response rate ( CRR ) six cycle chemotherapy - determine complete remission rate ( CR/CRr ) final treatment outcome completion treatment</brief_summary>
	<brief_title>Targeted BEACOPP Variants Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically proven classical Hodgkin lymphoma First diagnosis , previous treatment , age : 1860 year Stage IIB large mediastinal mass and/or extranodal lesion , stage III IV disease Composite lymphoma nodular lymphocyte predominant Hodgkin lymphoma ( NLPHL ) Previous malignancy Prior chemotherapy radiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>